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Introduction
Evidence-based guidelines are necessary to the appli-
cation of treatments for type 2 diabetes and to
ensure best practice in diabetes management
(Table 1) (1–6). To date, the only global guideline
for the management of type 2 diabetes is that pro-
posed by the International Diabetes Federation (IDF)
(1), although other guidelines with regional inﬂuence
have appeared, including the transatlantic consensus
guideline proposed jointly by the American Diabetes
Association (ADA) and the European Association for
the Study of Diabetes (EASD) (2,3). An expert
group in the Middle East adapted the ADA⁄EASD
recommendations for use in the Arab world in 2007,
particularly with reference to the low rate of medical
insurance coverage and the variable provision of spe-
cialist diabetes services and diabetes education across
the region (4).
These guidelines, described in detail below, have
increasingly favoured the initiation of oral antidia-
betic pharmacotherapy with metformin. Although it
is difﬁcult to deﬁne the frequency of use of metfor-
min as initial pharmacotherapy for type 2 diabetes in
the Middle East, this treatment may be underused in
the region. Survey evidence suggests that about four-
ﬁfths of the recently diagnosed type 2 diabetes
patients in the UK start oral antidiabetic drug treat-
ment with metformin, compared with only about
one-third in the Middle East (Figure 1). It appears,
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What’s known
• The burden of diabetes is high in the Middle
East.
• The Middle East has largely been overlooked by
guideline writers.
What’s new
• Type 2 diabetes is often sub-optimally managed
in the Middle East.
• The pathophysiology of the disease in Middle
Eastern patients resembles that in other
populations, but few clinical trials recruited
Middle Eastern populations.
• Metformin appears to be under-used in the
region, and should be considered as initial
pharmacologic therapy, in line with international
guidelines for the management of type 2
diabetes.
1King Khalid University
Hospital, King Saud University,
Riyadh, Saudi Arabia
2Dasman Center for Research
and Treatment of Diabetes,
Dasman, Kuwait
3Alexandria University,
Alexandria, Egypt
4American University of Beirut,
Beirut, Lebanon
5Joslin Diabetes Center, Dubai,
United Arab Emirates
6Mutah University, Mutah,
Karak, Jordan
7Al Hada Armed Forces
Hospital, Taif, Saudi Arabia
8Imperial College, London, UK
Correspondence to:
Dr Mohamed Al-Maatouq,
Department of Medicine (38),
College of Medicine & King
Khalid University Hospital, King
Saud University, P O Box 2925,
Riyadh 11461, Saudi Arabia
Tel.: + 966 1 4671497
Fax: + 966 1 4671494
Email: mmaatouq@ksu.edu.sa
Disclosures
The recommendations given
above arose from a meeting of
an expert panel of physicians
from Middle-Eastern countries
supported by an educational
grant from Merck Serono, and
authors received an honorarium
for their contributions. Dr SH
Assaad is a Principal
Investigator for a research
project supported by Merck
Serono.
Re-use of this article is
permitted in accordance with
the Terms and Conditions set
out at http://www3.interscience.
wiley.com/authorresources/
onlineopen.html
CONSENSUS
ª 2009 Blackwell Publishing Ltd Int J Clin Pract, January 2010, 64, 2, 149–159
doi: 10.1111/j.1742-1241.2009.02235.x 149therefore, that metformin may be underused in the
Middle East, compared with western countries, and
that a consensus guideline on diabetes management
directly relevant to the countries of the region may
be required. This article considers the nature and
management of type 2 diabetes in the region, with
particular reference to the therapeutic use of metfor-
min, and proposes recommendations on the initia-
tion of antidiabetic therapy for Middle-Eastern
patients with type 2 diabetes.
Pathophysiology of type 2 diabetes
The progression of hyperglycaemia in type 2 diabetes
is driven by b-cell dysfunction occurring against a
background of insulin resistance (1,2). The develop-
ment of insulin resistance is usually an early event in
the pathogenesis of type 2 diabetes and requires
increased secretion of insulin to maintain euglyca-
emia. As b-cell function continues to decline, insufﬁ-
cient insulin is secreted to control blood glucose
adequately and chronic fasting and⁄or postprandial
hyperglycaemia becomes established. Eventually,
insulin secretion often declines to the point where
exogenous injections of insulin are required. Data
from the UK Prospective Diabetes Study (UKPDS)
suggest that about half of a patient’s original b-cell
function have already been lost by the time diabetes
is diagnosed (7).
Most oral antidiabetic treatments target insulin
resistance or b-cell dysfunction as their primary mech-
anisms of action (2). Metformin addresses insulin
resistance primarily in the liver and skeletal muscle
and mainly reverses hyperglycaemia through a reduc-
tion in hepatic glucose production, while the thiazo-
lidinediones increase whole-body insulin-mediated
glucose disposal to a greater extent than metformin
(8). Sulfonylureas and drugs acting via the incretin
system, dipeptidyl peptidase-4 (DPP-4) inhibitors (in-
cretin enhancers) and glucagon-like peptide 1 (GLP-1)
agonists (incretin mimetics), increase insulin secretion
with the incretin drugs also normalising glucagon
secretion. Finally, a-glucosidase inhibitors slow and
smooth the absorption of glucose from the gastroin-
testinal tract, reducing postprandial hyperglycaemia. It
is important to note that hyperglycaemia per se is toxic
to the b-cell; thus, any treatment which reduces the
severity of hyperglycaemia is likely to improve b-cell
function to some extent over the short term.
Type 2 diabetes in the Middle East
Increasing burden of diabetes
The burden of diabetes in the Middle East is high.
Figure 2 compares the recently reported prevalence
of diabetes in adults (20–79 years) in countries in
the region alongside the projected prevalence for
2025, according to the IDF (9). The prevalence of
diabetes in most Middle-Eastern countries is already
Table 1 Overview of leading guidelines for the management of type 2 diabetes
Reach Guideline Year
Goal HbA1c
(%)
BMI deﬁnition
of overweight
Recommendations for initiating pharmaco-
logic antidiabetic therapy*
Overweight Non-overweight
Global IDF (1) 2005 6.5 None given* Metformin preferred Metformin or SU
Transatlantic ADA⁄EASD (2,3) 2008 7.0 None given Metformin preferred
Regional Middle East (ADA⁄EASD) (4) 2007 7.0 None given Metformin preferred
Asia-Paciﬁc (IDF) (5) 2005 6.5 Ethnic-speciﬁc Metformin Metformin, TZD,
SU⁄meglitinide, AGI
Latin America (ALAD) (6) 2000 7.0 ‡ 27 kg⁄m
2 Metformin SU
*Oral antidiabetic therapy is prescribed after a trial of lifestyle intervention except for American Diabetes Association (ADA) ⁄European Association for the Study
of Diabetes (EASD) and Middle-eastern guideline where metformin should be prescribed alongside lifestyle intervention at the time of diagnosis of type 2 diabetes.
First issued in 2006 and updated in 2008. The International Diabetes Federation (IDF) now propose ethnic-speciﬁc cut-off values for waist circumference to
diagnose abdominal obesity. AGI, a-glucosidase inhibitor; ALAD, asociacio ´n latinoamericana de diabetes; SU, sulfonylurea; TZD, thiazolidinedione.
Figure 1 Use of metformin as initial oral antidiabetic
pharmacotherapy in the Middle East (2008) and the UK
(2007).
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set to increase markedly in the region by 2025. While
the worldwide prevalence of diabetes in 2025 will be
almost 25% higher than the value in 2003, the preva-
lence of diabetes in the IDF Middle East and North
Africa region is set to increase by 81% during this
period. Taking into account the projected increases
in populations of these countries, this means that the
number of people with diabetes in the Middle East is
set to be more than double (9).
When considering the data shown in Figure 2, it is
important to note that the results of epidemiological
surveys depend critically on the precise methodology
used and the nature of the populations studied.
Moreover, the projected prevalence estimates for
2025 are based on projected changes in population
and body weight. These estimates should be treated
as a guide rather than as a deﬁnitive and quantitative
determinant of prevalence and should be considered
alongside other studies, wherever available. For
example, the age-adjusted prevalence of diabetes
among a nationally representative population of
17,232 subjects in Saudi Arabia was 22% (10), which
is higher than the estimate from the IDF shown in
Figure 2. Another study based on a nationally repre-
sentative sample of 5844 subjects in the United Arab
Emirates in 1999–2000 demonstrated an age-standar-
dised prevalence of diabetes of 21% (22% in men
and 21% in women), which is closer to the current
estimate from the IDF (11). A high and relatively
transient expatriate population also complicates
measurements of disease prevalence in the Middle
East. In the study described above, the prevalence of
diabetes was higher in Emirati citizens than in
expatriates (25% vs. 13–19%).
A substantial burden of non-diabetic dysglycaemia
[impaired glucose tolerance (IGT) or impaired fast-
ing glucose (IFG)] provides a large reservoir of
patients at high risk of developing type 2 diabetes in
the Middle East, as elsewhere (Figure 2) (9). A high
prevalence of undiagnosed diabetes also contributes
to the problem. Population-based surveys in Saudi
Arabia, Egypt and the United Arab Emirates have
demonstrated a high prevalence of these conditions,
in addition to previously diagnosed diabetes
(10,12,13). Urbanisation, followed by access to high-
energy foods and adoption of sedentary habits, is an
important underlying cause of the increasing preva-
lence of diabetes and associated cardiovascular
disease in the Middle East, as in other regions
(10,14). The quality of diet is variable; however, a
study in randomly selected non-diabetic Egyptian
subjects concluded that their diet was similar to that
recommended by the Diabetes and Nutrition Study
Group of the European Association for the Study of
Diabetes (EASD) (15).
The cost of managing diabetes is high. The major-
ity of the cost of managing diabetes arises from the
management of diabetic complications, especially in
hospital. In the main analysis of the UKPDS, treat-
ment of complications accounted for 63% of overall
within-trial costs in the group randomised to receive
Figure 2 Increasing burden of dysglycaemia in the Middle East. Data shown are from the 15 countries from the
International Diabetes Federation (IDF) Middle East and North Africa region with the highest adult (20–79 years)
prevalence of diabetes in 2003, according to the IDF E-atlas of Diabetes (9). Data from Armenia and Pakistan were
omitted for clarity. IGT: impaired glucose tolerance
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calculated for overweight patients, where the man-
agement of complications accounted for 74% of
overall within-trial costs in the diet group (17). Few
health economic analyses have been conducted in the
Middle East. Patients with diabetes account for 2.6%
of all hospital admissions and 3.5% of all hospital
stays in Saudi Arabia (18). A report from a health
insurance company in Abu Dhabi, reported in the
press, claimed recently that the cost of managing dia-
betes in the UAE will reach Dh 10 billion (US $2.7
billion) by 2020 (19). There is no doubt that the eco-
nomic burden of diabetes will continue to increase
as the prevalence of the disease increase in Middle-
Eastern countries.
Clinical characteristics of diabetes in the
Middle East
The clinical characteristics of diabetes have not been
well studied in many countries of the region. However,
it is clear that obesity (especially abdominal obesity),
family history of diabetes and other commonly occur-
ring cardiometabolic risk factors are associated with a
signiﬁcant increase in the risk of developing type 2
diabetes in this population, as has been demonstrated
elsewhere (20,21). A large survey in Saudi Arabia
found that 36% of subjects (26% of men and 44% of
women) were obese (22). However, a genetic predis-
position to type 2 diabetes, exacerbated by a tendency
towards consanguinity and a relatively high prevalence
of cardiometabolic risk factors associated with
the metabolic syndrome, may contribute to the high
prevalence of diabetes in the Middle East (10,23).
Indeed, cardiometabolic risk factors are common
among Middle-Eastern type 2 diabetes patients
(24–27). Large surveys in Saudi Arabia (n = 17,230,
age 30–70 years) (25) and Egypt (n = 7915, age
> 25 years) demonstrated a prevalence of hyperten-
sion of 26%, in each case (only 58% had normal
blood pressure according to JNC-V guidelines in
Egypt, with the remainder having high-normal blood
pressure) (26,27). Only 38% of patients with hyper-
tension were aware of their condition in Egypt (27).
Hypertension was strongly associated with obesity
and other cardiometabolic risk factors in both coun-
tries. The atherogenic dyslipidaemia phenotype is
also common, and about one patient in ﬁve among a
randomly selected Saudi cohort of 507 patients with
type 2 diabetes was found to have low HDL-C
[deﬁned as < 35 mg⁄dl (0.9 mmol⁄l) in men and
<4 5m g⁄dl (1.2 mmol⁄l) in women] (28). Similarly,
the prevalence of HDL-C < 35 mg⁄dl (0.9 mmol⁄l)
was 25% in 1733 men and women aged > 25 years
surveyed in the Egyptian National Hypertension
Project (29).
Epidemiological studies in the region may be com-
plicated by the relatively high proportion of expatri-
ate workers in some Middle-Eastern countries.
However, another study from Saudi Arabia showed
that the prevalence of individual cardiometabolic risk
factors (dyslipidaemia, smoking, obesity, high blood
pressure and poor glycaemic control) differed little
among Saudi and non-Saudi patients with type 2
diabetes (30).
Survey evidence suggests a low success rate in
achieving targets for cardiometabolic risk factor con-
trol, with low proportions of a Saudi population
attending a hospital clinic achieving blood pressure
< 130⁄85 mmHg (60%), triglycerides < 2.3 mmol⁄l
(200 mg⁄dl) (35%), body mass index < 27 kg⁄m
2
(46%), LDL-C < 2.6 mmol⁄l (100 mg⁄dl) (18%), or
HDL-C > 1.1 mmol⁄l (43 mg⁄dl) (33%) (31). In the
Egyptian National Hypertension Project, only 24% of
patients received antihypertensive medication, and
only 8% of patients achieved JNC-V goals for blood
pressure (27). A similar low rate of control of hyper-
tension was observed in type 2 diabetes patients in
Jordan (32).
Although the association between type 2 diabetes
and cardiovascular risk has not been studied as
intensively in the Middle East as in other popula-
tions, there is evidence that a comparable relation-
ship exists between a diagnosis of diabetes and
adverse cardiovascular outcomes. The prevalence of
coronary artery disease in Emirati subjects tended to
increase consistent with the severity of dysglycaemia,
from prediabetes (4.7%) to undiagnosed (5.0%) or
diagnosed (10.5%) diabetes (12). A similar trend was
observed for peripheral vascular disease (3.6%, 5.0%
and 11.1% respectively) (12). Type 2 diabetes is also
a powerful risk factor for ischaemic stroke in the
region (33). Elevated fasting blood glucose has been
shown to promote the progression of coronary artery
disease in Lebanese patients (34).
The association between long-term hyperglycaemia
and an increased risk of microvascular diabetic com-
plications appears comparable for the Middle East
and elsewhere. A survey in Egypt conﬁrmed the high
prevalence of microvascular complications in an
Arab population with diabetes (Figure 3) (13). Else-
where, a survey in 1952 Saudi type 2 diabetes
patients admitted to hospital between 1989 and 2004
found an incidence of retinopathy of 32% (35), with
a corresponding ﬁgure of 24% from a survey in
Kuwait (2006) (36). These ﬁgures appear somewhat
lower than the prevalence of retinopathy in the newly
diagnosed population of the UKPDS, where the prev-
alence of retinopathy was 36% at baseline (37),
although they were considerably higher than the
corresponding ﬁgure of 8% for the Fenoﬁbrate
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(FIELD) Study (38). It is important to note that dif-
ferent deﬁnitions of retinopathy may make direct
comparisons difﬁcult between individual trials.
Nevertheless, the risk of progression of retinopathy was
increased by an increasing duration of diabetes, sub-
optimal glycaemic control and higher levels of blood
pressure in all these analyses in an apparently similar
manner. A similar relationship holds for nephropa-
thy: although the incidence of diabetes-related end-
stage renal failure appears to be lower in the Middle
East than in western countries, under-reporting of
the true prevalence may have underestimated the
true burden of this condition (39). A population-
based survey in the United Arab Emirates demon-
strated a prevalence of neuropathy of 35% among
patients with diabetes (12), while a single-centre sur-
vey at a Saudi Arabian diabetes clinic found that
56% of diabetic patients had symptomatic neuropa-
thy, with about half of the remainder having subclin-
ical, asymptomatic neuropathy (40). Figure 3 shows
the prevalence of neuropathy in Egypt in patients
stratiﬁed for different severities of dysglycaemia (13).
Poor glycaemic control is common in the
Middle East
Poor glycaemic control is common in the region.
The study conducted in Egypt, described above,
found mean HbA1C values of 9.2% in patients with
previously diagnosed diabetes and 8.7% in patients
with previously undiagnosed diabetes (13). A retro-
spective survey of 991 Saudi type 1 or type 2 diabetes
patients attending hospital diabetes clinics revealed
‘excellent’ blood glucose control [4–7 mmol⁄l
(72–126 mg⁄dl)] in only 21%, with ‘poor’ control
[> 10 mmol⁄l (180 mg⁄dl)] in > 40% (41). Another
survey from the same country showed that only 27%
of type 2 diabetes patients achieved HbA1C < 7.0%
(31). Somewhat better glycaemic control was demon-
strated in patients with diagnosed (mean HbA1C
8.3%) or undiagnosed (mean HbA1C 6.7%) diabetes
in the United Arab Emirates (12).
Important barriers to achieve successful treatment
outcomes differ between the Middle East and Europe.
Middle-Eastern states are far from homogenous in
demographic terms, with highly developed and
westernised areas often coexisting with relatively
undeveloped regions with high rates of poverty (14).
Access to healthcare, along with other basic amenities,
is often restricted, particularly in remote rural areas,
and the prevalence of cardiometabolic risk factors
may differ markedly between regions of the same
country (42). Other socioeconomic factors, such as
cultural traditions, education and income are also
important determinants of health outcomes. Thus,
the level of education was a powerful predictor of
knowledge of the both causes of coronary heart dis-
ease and of strategies to improve cardiovascular health
in a population of Saudi patients attending a primary
care health centre, although less than half of the
population as a whole knew about such issues (43).
Optimising the management of type 2
diabetes: metformin in comparison
withotheroralantidiabetic therapies
Efﬁcacy and tolerability
Table 2 shows an overall comparison of key proper-
ties of metformin that are relevant to its overall risk:
Figure 3 Prevalence of microvascular complications or cataract in a survey in Egypt. Albuminuria was deﬁned as a urinary
albumin:creatinine ratio > 100 mg⁄g. Clinical nephropathy was deﬁned as urinary albumin:creatinine ratio > 300 mg⁄g.
Drawn from data presented by Herman et al. (13)
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antidiabetic therapy (44). Metformin is as effective as
other oral antidiabetic agents, with little or no poten-
tial for clinically signiﬁcant hypoglycaemia, in con-
trast to sulfonylureas or meglitinides, which are
associated with a relatively high incidence of hypo-
glycaemia (44). Metformin can be combined with
members of any class of oral antidiabetic agents,
including insulin or the new incretin enhancers and
incretin mimetics. Indeed, metformin itself potenti-
ates the actions of endogenous GLP-1 to a clinically
signiﬁcant extent, through either inhibition of DPP-4
(45) or enhancement of GLP-1 secretion (46).
Importantly, metformin is not associated with
increases in body weight, unlike sulfonylureas and
thiazolidinediones; indeed, body weight is often
reduced during metformin treatment (47,48). The
main side effects of metformin occur in the gastroin-
testinal system (particularly diarrhoea). These can be
minimised by initiating treatment at a low dose
(500 mg) and titrating cautiously [the maximum
daily dosage for most patients will be in the region
of 1700 mg (2 · 850 mg) or 2000 mg (4 · 500 mg
or 2 · 1000 mg)]. An extended-release formulation
has been shown to improve gastrointestinal tolerabil-
ity in patients unable to tolerate standard immedi-
ate-release metformin (49). Incretin mimetics also
induce gastrointestinal side effects (mainly nausea),
although this is described as transient.
Safety
Many publications have linked metformin with an
increased risk of lactic acidosis (44). A Cochrane
review conﬁrmed the similar risk of lactic acidosis
for metformin and non-metformin treatments for
diabetes, with upper estimates of the risk of 8.4 and
9 patients per 100,000 patient-years respectively (50).
A more recent meta analysis, including three
additional randomised, controlled studies, has
conﬁrmed this outcome (48). Finally, the Compara-
tive Outcomes Study of Metformin Intervention vs.
Conventional (COSMIC) Approach Study, a 1-year
randomised comparison of metformin and other
diabetes treatments conducted under usual care
conditions in 8732 patients, found no cases of lactic
acidosis (51). Accordingly, the risk of lactic acidosis
with metformin is not higher than that with other
antidiabetic therapies, when the contraindications
and precautions of metformin are respected.
The potential of thiazolidinediones to increase car-
diovascular risk (particularly myocardial infarction)
is controversial, and previous meta analyses have
provided conﬂicting results, especially with respect to
rosiglitazone (52–54). Pioglitazone has not been asso-
ciated with increased cardiovascular risk to the same
extent and has been shown to exert a modest
improvement in secondary cardiovascular end-points
in a randomised trial (see below). Current
ADA⁄EASD management guidelines in type 2 diabe-
tes suggest that rosiglitazone should be avoided and
states that the use of thiazolidinediones in general is
less well-validated than the addition of a sulfonylurea
or insulin to metformin when antidiabetic combina-
tion therapy is required (2). Thiazolidinediones are
also associated with an increased risk of oedema-
associated heart failure (54,55) and have also been
shown to slightly but signiﬁcantly increase the risk of
distal limb fractures in women (55). These effects
have been demonstrated with both rosiglitazone and
pioglitazone.
Incretin enhancers act via blockade of DPP-4,
which is present in immune cells. Although there
Table 2 Comparison of classes of oral antidiabetic agents (45)
Met SU Meg TZD DPP-4 inh GLP-1 agonists AGI
Expected ﬂHbA1c* 1.0–2.0 1.0–2.0 0.5–1.5 0.5–1.4 0.5–0.8 0.5–1.0 0.5–0.8
Hypoglycaemia risk Very low High High Very low Low Low Very low
Effects on body weight Neutral or
weight loss
Weight gain Weight gain Weight gain Neutral Weight loss Neutral
Other side effects GI symptoms None None Oedema None Nausea Frequent GI
symptoms
Other safety issues Lactic acidosis None None Heart failure,
fractures
Skin, immune
disorders?
Pancreatitis? None
CV outcomes ﬂCV events
(UKPDS)
Neutral Neutral Conﬂicting
data
No data No data ﬂCV events
(meta analysis)
Cost Low (generic) Low (generic) Low (generic) Very high Very high Very high High
Met, metformin; SU, sulfonylurea; Meg, meglitinide; TZD, thiazolidinediones; AGI, a-glucosidase inhibitors; inh, inhibitors. *As proposed in the joint guideline
proposed by the American Diabetes Association and the European Association for the Study of Diabetes (2) See text for other references.
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an association between DPP-4 inhibition and
adverse effects on the immune system, a Cochrane
analysis has called for more data (56), and the
ADA⁄EASD guidelines acknowledge the theoretical
potential for immune dysregulation with these
agents (2,3). Preclinical studies suggest that a high
selectivity for DPP-4 over other similar enzymes is
necessary to reduce the risk of cutaneous adverse
events, and the US regulatory authorities are
currently reviewing the therapeutic proﬁle of
vildagliptin with regard to this issue (57). Cases of
pancreatitis have been reported with incretin
mimetics, although the clinical signiﬁcance of these
observations is uncertain.
Cardiovascular outcomes
Randomisation to metformin in the UKPDS was
associated with signiﬁcant improvement in a range
of cardiovascular end-points, with these beneﬁts
maintained after 10 years of posttrial monitoring
during which patients returned to the usual care of
their physician (Figure 4) (58,59). A recent rando-
mised, placebo-controlled trial evaluated the effects
of metformin on clinical outcomes in 390 insulin-
treated type 2 diabetes patients followed for 4.3 years
(60). Metformin did not signiﬁcantly inﬂuence the
primary cardiovascular end-point (a composite of
microvascular and macrovascular end-points), but
signiﬁcantly reduced the risk of a secondary
end-point comprising a composite of macrovascular
end-points by 40% [hazard ratio 0.60 (95% CI,
0.40–0.92), p = 0.04].
Additional observational analyses, reviewed
elsewhere (44), have added to the evidence base for
cardiovascular protection with metformin. One of
these was a post hoc analysis of the prevention of
restenosis with tranilast and its outcomes (PRESTO)
trial, involving analysis of data from 1997 patients
with type 2 diabetes at baseline who received either
metformin or other oral antidiabetic treatments that
do not inﬂuence the action of insulin as their
primary mechanism (i.e. patients receiving a thiazo-
lidinedione wereexcluded)(61).Patientsinthemetfor-
min group beneﬁted from lower adjusted risks of any
clinical event [risk reduction (RR) 28%, p = 0.005],
myocardial infarction (RR 69%, p = 0.002) or all-cause
mortality(RR 61%, p = 0.007).
Pioglitazone improved secondary cardiovascular
end-points in the PROACTIVE trial (62–64),
although the continuing controversy regarding the
cardiovascular safety of these agents is discussed
above. Although a meta analysis of acarbose trials sug-
gested a reduction in cardiovascular events (65), no
other class of oral antidiabetic agent has demonstrated
unequivocal cardiovascular protection. The long-term
cardiovascular safety proﬁle of agents acting via the
incretin system is largely unknown, because of the
limited clinical experience available for these agents.
Cost
The cost of treatment is another important issue
inﬂuencing the access of many patients to healthcare.
Metformin and some sulfonylureas are available as
generic preparations; therefore limiting their cost.
However, the quality of some of these generic prepa-
rations remains a cause for concern. Thiazolidinedi-
ones, a-glucosidase inhibitors and agents acting via
the incretin system are branded preparations and are
thus more expensive.
Figure 4 Effects of metformin on clinical cardiovascular outcomes in the UKPDS. The reference group for risk reductions
was patients randomised to diet-based treatment. All risk reductions were signiﬁcantly different except those for stroke.
MI: myocardial infarction. Drawn from data presented in Refs (59,60)
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The principal factors in selecting an oral antidiabetic
agent are its antihyperglycaemic efﬁcacy, together
with other properties that suggest a potential long-
term beneﬁt (2,3). Clinical studies have documented
beneﬁcial metabolic effects potentially in metformin-
treated patients in a range of conditions associated
with insulin resistance (44). These include non-alco-
holic fatty liver disease (and its more prognostically
serious form, non-alcoholic steatohepatitis, which are
closely associated with the metabolic syndrome) (66),
polycystic ovary syndrome [(PCOS) the most com-
mon cause of infertility in western populations] (67),
HIV-associated lipodystrophy (secondary to an
induced form of insulin resistance caused by protease
inhibitors) (68) and the prevention of weight gain
induced by second-generation antipsychotic agents
(69). Observational evidence also supports an anti-
neoplastic effect of metformin, consistent with its
activation by metformin of the enzyme, AMP-
activated protein kinase, which in turn activates a
tumour suppressor, LKB1 (70,71). To date, metfor-
min is not indicated for these conditions, although
management guidelines in this area identify a place
for metformin in the management of PCOS (44).
Although these effects are speculative at this time,
they may be of relevance to individual patients dis-
playing these conditions at presentation, and further
clinical research will properly deﬁne the potential of
metformin in these areas.
The role of oral antidiabetic therapy in the man-
agement of gestational diabetes requires further
research, not least as women with PCOS may become
pregnant while receiving treatment for this condition.
At present, insulin is the mainstay of the management
of gestational diabetes, and oral agents are discontin-
ued. However, a recent systematic review has shown
that the use of oral antidiabetic therapy, including
metformin, was not associated with an increased risk
of adverse foetal outcomes, and a lower rate of
neonatal hypoglycaemia, relative to insulin (72).
Guidelines
Data on the effectiveness of antidiabetic interventions
in Middle-Eastern subjects are scarce. Accordingly, it
is reasonable to assess individual therapies on the
basis of their therapeutic proﬁles demonstrated in
other populations, especially as the aetiology and
pathogenesis of diabetes in the Middle East and
other regions appear comparable (as described
above). Table 1 summarises the key features of sev-
eral leading guidelines. A joint guideline issued by
the American Diabetes Association (ADA) and the
EASD (2,3), and an adaptation of these guidelines
for Middle-Eastern patients (4), recommend immedi-
ate prescription of metformin alongside lifestyle
intervention (this therapy is continued throughout
the course of diabetes) for all patients with type 2
diabetes and HbA1C above 7.0% who are able to
receive metformin. This is followed, when required,
by combination therapy with a sulfonylurea or basal
insulin [i.e. neutral protamine hagedorn (NPH) insu-
lin or newer insulin analogues], which are considered
to be well-validated therapies. Where metformin-
sulfonylurea combinations do not control glycaemia
sufﬁciently, patients should receive metformin plus
basal insulin. Combinations based on metformin
with pioglitazone (rosiglitazone is not recommended
following recent concerns over the risk:beneﬁt proﬁle
of this agent) or an incretin mimetic (GLP-1 agonist)
are included as ‘less well-validated therapy’. Eventu-
ally, all patients requiring insulin should progress to
treatment with lifestyle intervention, metformin and
an intensive insulin regimen.
The major international guideline issued by the
IDF (1) and an adaptation of these guidelines for the
Asian-Paciﬁc region (5) recommended prescription
of metformin as ﬁrst-line pharmacological antidia-
betic therapy for patients without contraindications,
who did not respond sufﬁciently well to a trial of
lifestyle intervention. Sequential intensiﬁcation of
oral antidiabetic therapy is required up to and
including insulin-based treatment. Importantly, the
lifestyle intervention is maintained throughout the
course of the disease, as in the ADA⁄EASD guideline.
The IDF published a guideline speciﬁcally addressing
the control of postmeal glucose in 2007 (73). This
guideline recognises the importance of postprandial
glucose as a risk factor for long-term diabetic com-
plications and advocates the control of 2-h postmeal
glucose to <7.8 mmol⁄l (140 mg⁄dl).
Ramadan is a religious observance of the Muslim
faith that involves abstinence from food and drink
between dawn and sunset for a period of one month.
Fasting during Ramadan alters the delivery of antidi-
abetic treatment for an estimated 40–50 million
Muslim patients with diabetes worldwide (74). Guid-
ance on optimising blood glucose control, while
minimising the risk of hypoglycaemia, hyperglyca-
emia, ketoacidosis, dehydration and thrombosis, is
required for these patients (74,75). It is important
that patients should not fast if they are unwell and
should end their fast immediately if blood glucose
falls below 60 mg⁄dl (3.3 mmol⁄l). The fast should
also be broken if blood glucose is < 70 mg⁄dl
(3.9 mmol⁄l), especially if the patient is taking insulin
or insulin secretagogues. Oral antidiabetic agents with
a low risk of hypoglycaemia, such as metformin, are
preferred. Individually tailored insulin regimens, with
divided doses or basal and⁄or short- or rapid-acting
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may reduce the risk of hypoglycaemia for patients
who require treatment with insulin. Educational
counselling and maintaining contact with the physi-
cian during Ramadan are also important.
Recommendations for type 2 diabetes
management in the Middle East
Recommendations for the use of oral antidiabetic
therapy in the management of type 2 diabetes are
summarised in Figure 5. The initiation of oral antidi-
abetic pharmacotherapy with metformin, alongside
lifestyle intervention, remains the therapeutic strategy
best supported by current clinical evidence. This is
particularly the case in countries like those of the
Middle East, where the cost of medication is an
important issue for many patients.
Treatment may be initiated with lifestyle interven-
tion. Even a brief trial of lifestyle intervention, of as
little as 1 month, is often useful in indicating the
potential of this treatment to impact substantially on
hyperglycaemia. A separate trial of lifestyle intervention
also emphasises the importance of this treatment
in its own right and helps to educate patients that it
is not an optional extra to pharmacotherapy. It
should be noted; however, that access to healthcare
may represent an important barrier to treatment for
many Middle-Eastern patients, and that the addi-
tional clinic visits necessary to administer a trial of
lifestyle intervention may be problematic in some cases.
For these patients, metformin may be co-prescribed
at this time, as per the ADA⁄EASD guideline,
according to the physician’s judgement. Basal insulin
(NPH or analogue) or a sulfonylurea is the preferred
next step in treatment intensiﬁcation, although other
agents may be more appropriate for an individual
patient (e.g. a patient susceptible to or concerned
about hypoglycaemia, with contraindications to or
intolerance of metformin). Patients maintained on
oral combinations then receive basal insulin, with
intensive insulin regimens (with or without oral
agents) as the ﬁnal step.
Conclusions
The application of evidence-based therapy for
patients with type 2 diabetes is essential given the
projected large increases in the prevalence of type 2
diabetes in countries of the Middle East. Although
the number of treatments for type 2 diabetes has
increased in recent years, metformin plus lifestyle
intervention remains the preferred strategy for the
initiation of oral antidiabetic pharmacotherapy.
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